Patrik Nasr

8.7k total citations · 5 hit papers
54 papers, 5.9k citations indexed

About

Patrik Nasr is a scholar working on Epidemiology, Hepatology and Pathology and Forensic Medicine. According to data from OpenAlex, Patrik Nasr has authored 54 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Epidemiology, 28 papers in Hepatology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Patrik Nasr's work include Liver Disease Diagnosis and Treatment (52 papers), Liver Disease and Transplantation (26 papers) and Alcohol Consumption and Health Effects (15 papers). Patrik Nasr is often cited by papers focused on Liver Disease Diagnosis and Treatment (52 papers), Liver Disease and Transplantation (26 papers) and Alcohol Consumption and Health Effects (15 papers). Patrik Nasr collaborates with scholars based in Sweden, United States and United Kingdom. Patrik Nasr's co-authors include Mattias Ekstedt, Stergios Kechagias, Hannes Hagström, Per Stål, Rolf Hultcrantz, Mats Fredrikson, Ulf Hammar, Giada Sebastiani, Vincent Wai‐Sun Wong and Zobair M. Younossi and has published in prestigious journals such as Gastroenterology, Hepatology and Scientific Reports.

In The Last Decade

Patrik Nasr

51 papers receiving 5.8k citations

Hit Papers

Fibrosis stage is the str... 2014 2026 2018 2022 2014 2017 2017 2020 2024 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
    2014 1.7k citations Mattias Ekstedt, Hannes Hagström et al. profile →
  2. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
    2017 1.3k citations Mattias Ekstedt, Hannes Hagström et al. profile →
  3. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
    2017 732 citations Hannes Hagström, Patrik Nasr et al. profile →
  4. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    2020 681 citations Hannes Hagström, Patrik Nasr et al. profile →
  5. Natural history and progression of metabolic dysfunction-associated steatotic liver disease
    2024 93 citations Hannes Hagström, Ying Shang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrik Nasr Sweden 23 5.6k 3.1k 2.1k 970 788 54 5.9k
Phunchai Charatcharoenwitthaya Thailand 26 4.9k 0.9× 2.9k 0.9× 1.9k 0.9× 695 0.7× 1.3k 1.6× 123 5.7k
Janus P. Ong United States 31 5.5k 1.0× 2.9k 0.9× 2.1k 1.0× 969 1.0× 1.1k 1.4× 72 6.3k
Jason M. Hui Australia 14 6.0k 1.1× 3.3k 1.0× 2.2k 1.0× 863 0.9× 983 1.2× 19 6.6k
Fabio Nascimbeni Italy 28 4.1k 0.7× 1.5k 0.5× 2.2k 1.1× 785 0.8× 563 0.7× 54 4.8k
Etsuko Hashimoto Japan 35 4.4k 0.8× 2.3k 0.7× 1.8k 0.8× 759 0.8× 771 1.0× 107 5.2k
Eduardo Vilar‐Gómez United States 26 3.9k 0.7× 1.9k 0.6× 1.8k 0.8× 582 0.6× 647 0.8× 76 4.3k
Alina M. Allen United States 32 3.8k 0.7× 2.3k 0.7× 1.2k 0.6× 504 0.5× 837 1.1× 107 4.5k
Manirath Srishord United States 13 3.6k 0.6× 1.6k 0.5× 1.8k 0.8× 668 0.7× 606 0.8× 28 4.0k
Aynur Ünalp United States 17 4.1k 0.7× 1.7k 0.5× 2.1k 1.0× 616 0.6× 673 0.9× 32 4.6k
Fernando Bril United States 33 4.8k 0.9× 1.5k 0.5× 2.9k 1.4× 706 0.7× 961 1.2× 85 5.6k

Countries citing papers authored by Patrik Nasr

Since Specialization
Citations

This map shows the geographic impact of Patrik Nasr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrik Nasr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrik Nasr more than expected).

Fields of papers citing papers by Patrik Nasr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrik Nasr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrik Nasr. The network helps show where Patrik Nasr may publish in the future.

Co-authorship network of co-authors of Patrik Nasr

This figure shows the co-authorship network connecting the top 25 collaborators of Patrik Nasr. A scholar is included among the top collaborators of Patrik Nasr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrik Nasr. Patrik Nasr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carlhäll, Carl‐Johan, Pontus Henriksson, Stergios Kechagias, et al.. (2025). Clinically available predictors of obstructive sleep apnoea requiring treatment in type 2 diabetes patients in primary care. Scientific Reports. 15(1). 8710–8710.
2.
Carlhäll, Carl‐Johan, Tino Ebbers, Pontus Henriksson, et al.. (2025). Evaluating the prevalence and severity of metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. Journal of Internal Medicine. 298(3). 173–187. 3 indexed citations
3.
4.
Åberg, Mikael, Håkan Åhlström, Paul Hockings, et al.. (2025). Proteomic signatures for fibrosis in MASLD: a biopsy-proven dual-cohort study. Scandinavian Journal of Gastroenterology. 60(6). 597–605.
5.
Kechagias, Stergios, et al.. (2024). Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant. Scandinavian Journal of Gastroenterology. 59(6). 737–741. 1 indexed citations
6.
Nasr, Patrik, Mikael Forsgren, Nils Dahlström, et al.. (2023). A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol. BMC Gastroenterology. 23(1). 454–454. 3 indexed citations
7.
Nasr, Patrik, Erik von Seth, Raphaela Mayerhofer, et al.. (2023). Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019. European Journal of Epidemiology. 38(9). 973–984. 15 indexed citations
8.
Stål, Per, Patrik Nasr, Mattias Ekstedt, et al.. (2023). Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD. JHEP Reports. 6(2). 100915–100915. 16 indexed citations
9.
10.
Ericson, Elke, Anne‐Christine Andréasson, Carly I. Dix, et al.. (2022). Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications. 6(10). 2689–2701. 14 indexed citations
11.
Kechagias, Stergios, et al.. (2022). Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. HORMONES. 21(3). 349–368. 15 indexed citations
12.
Nasr, Patrik, et al.. (2021). Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scandinavian Journal of Gastroenterology. 57(1). 60–69. 6 indexed citations
13.
Hagström, Hannes, Dawei Bu, Patrik Nasr, et al.. (2021). Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scandinavian Journal of Gastroenterology. 56(4). 437–442. 9 indexed citations
14.
Nasr, Patrik, Simone Ignatova, Peter Lundberg, Stergios Kechagias, & Mattias Ekstedt. (2021). Low hepatic manganese concentrations in patients with hepatic steatosis – A cohort study of copper, iron and manganese in liver biopsies. Journal of Trace Elements in Medicine and Biology. 67. 126772–126772. 22 indexed citations
15.
Nasr, Patrik, Nils Dahlström, Karin Rådholm, et al.. (2021). Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterology. 21(1). 180–180. 8 indexed citations
16.
Forsgren, Mikael, Patrik Nasr, Markus Karlsson, et al.. (2020). Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scandinavian Journal of Gastroenterology. 55(7). 848–859. 19 indexed citations
17.
Nasr, Patrik, et al.. (2020). Modifiers of Liver-Related Manifestation in the Course of NAFLD. Current Pharmaceutical Design. 26(10). 1062–1078. 9 indexed citations
18.
Nasr, Patrik, Mats Fredrikson, Mattias Ekstedt, & Stergios Kechagias. (2020). The amount of liver fat predicts mortality and development of type 2 diabetes in non‐alcoholic fatty liver disease. Liver International. 40(5). 1069–1078. 39 indexed citations
19.
Hagström, Hannes, Patrik Nasr, Mattias Ekstedt, et al.. (2018). Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 17(6). 1148–1156.e4. 85 indexed citations
20.
Ekstedt, Mattias, Patrik Nasr, & Stergios Kechagias. (2017). Natural History of NAFLD/NASH. Current Hepatology Reports. 16(4). 391–397. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Phunchai Charatcharoenwitthaya Breakdown of academic impact, for papers by Janus P. Ong Breakdown of academic impact, for papers by Jason M. Hui Breakdown of academic impact, for papers by Fabio Nascimbeni Breakdown of academic impact, for papers by Etsuko Hashimoto Breakdown of academic impact, for papers by Eduardo Vilar‐Gómez Breakdown of academic impact, for papers by Alina M. Allen Breakdown of academic impact, for papers by Manirath Srishord Breakdown of academic impact, for papers by Aynur Ünalp Breakdown of academic impact, for papers by Fernando Bril
Rankless by CCL
2026